Century Therapeutics, Inc. Stock-Based Compensation
Century Therapeutics, Inc. (IPSC) reported Stock-Based Compensation of $3.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.95M, a 12.24% decline year-over-year.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.45M, a 40.44% decline year-over-year.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.30M, a 51.13% decline year-over-year.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $892.00K, a 73.12% decline year-over-year.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.84M, a 46.09% decline from fiscal 2024.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $12.69M, a 13.23% decline from fiscal 2023.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $14.62M, a 37.05% increase from fiscal 2022.
- Century Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.67M, a 128.85% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.40M 10-Q · filed 2026-08-12 | $4.70M derived: sum of 3 quarters · filed 2026-08-12 | $5.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.45M 10-Q · filed 2026-05-13 | $2.75M derived: sum of 2 quarters · filed 2026-05-13 | $3.64M derived: sum of 3 quarters · filed 2026-05-13 | $5.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.19M derived: sum of 2 quarters · filed 2026-03-12 | $4.41M derived: sum of 3 quarters · filed 2026-08-12 | $6.84M 10-K · filed 2026-03-12 |
| 2025-09-30 | $892.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.11M derived: sum of 2 quarters · filed 2026-08-12 | $5.54M 10-Q · filed 2025-11-13 | $8.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.65M 10-Q · filed 2026-08-12 | $7.31M derived: sum of 3 quarters · filed 2026-08-12 | $10.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.43M 10-Q · filed 2026-05-13 | $5.09M derived: sum of 2 quarters · filed 2026-05-13 | $8.40M derived: sum of 3 quarters · filed 2026-05-13 | $11.91M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.98M derived: sum of 2 quarters · filed 2026-03-12 | $9.48M derived: sum of 3 quarters · filed 2026-03-12 | $12.69M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.82M derived: sum of 2 quarters · filed 2025-11-13 | $10.03M 10-Q · filed 2025-11-13 | $13.59M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $6.71M 10-Q · filed 2025-08-14 | $10.27M derived: sum of 3 quarters · filed 2025-08-14 | $14.25M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.21M 10-Q · filed 2025-05-15 | $6.77M derived: sum of 2 quarters · filed 2025-05-15 | $10.75M derived: sum of 3 quarters · filed 2025-05-15 | $14.03M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $7.54M derived: sum of 2 quarters · filed 2025-03-19 | $10.82M derived: sum of 3 quarters · filed 2025-03-19 | $14.62M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.26M derived: sum of 2 quarters · filed 2024-11-05 | $11.06M 10-Q · filed 2024-11-05 | $13.79M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.08M 10-Q · filed 2024-08-08 | $9.81M derived: sum of 3 quarters · filed 2024-08-08 | $12.60M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.80M 10-Q · filed 2024-05-09 | $6.53M derived: sum of 2 quarters · filed 2024-05-09 | $9.31M derived: sum of 3 quarters · filed 2024-05-09 | $12.09M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.52M derived: sum of 2 quarters · filed 2024-03-14 | $8.29M derived: sum of 3 quarters · filed 2024-03-14 | $10.67M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.56M derived: sum of 2 quarters · filed 2023-11-09 | $7.94M 10-Q · filed 2023-11-09 | $9.57M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $5.15M 10-Q · filed 2023-08-09 | $6.79M derived: sum of 3 quarters · filed 2023-08-09 | $8.01M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $2.38M 10-Q · filed 2023-05-11 | $4.02M derived: sum of 2 quarters · filed 2023-05-11 | $5.24M derived: sum of 3 quarters · filed 2023-05-11 | $6.95M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.86M derived: sum of 2 quarters · filed 2023-03-16 | $4.57M derived: sum of 3 quarters · filed 2023-03-16 | $4.66M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.93M derived: sum of 2 quarters · filed 2022-11-10 | $3.03M 10-Q · filed 2022-11-10 | $3.40M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.81M 10-Q · filed 2022-08-11 | $2.18M derived: sum of 3 quarters · filed 2022-08-11 | $2.32M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $95.00K 10-Q · filed 2022-05-16 | $469.00K derived: sum of 2 quarters · filed 2022-05-16 | $613.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $518.00K derived: sum of 2 quarters · filed 2022-03-17 | $876.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $502.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $358.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |